| Primary |
| Antiviral Prophylaxis |
43.3% |
| Premature Baby |
14.3% |
| Bronchopulmonary Dysplasia |
10.8% |
| Heart Disease Congenital |
6.1% |
| Cardiac Disorder |
3.8% |
| Respiratory Syncytial Virus Infection |
3.8% |
| Product Used For Unknown Indication |
3.3% |
| Prophylaxis |
2.6% |
| Vitamin Supplementation |
2.5% |
| Immunisation |
1.6% |
| Pulmonary Hypertension |
1.2% |
| Respiratory Disorder |
1.1% |
| Drug Use For Unknown Indication |
1.0% |
| Cardiac Failure |
0.8% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Cardiomyopathy |
0.7% |
| Pneumonia |
0.7% |
| Diuretic Therapy |
0.6% |
| Infection Prophylaxis |
0.6% |
| Blood Pressure |
0.5% |
|
| Bronchiolitis |
14.4% |
| Respiratory Syncytial Virus Infection |
11.5% |
| Death |
10.9% |
| Vomiting |
6.9% |
| Pyrexia |
6.1% |
| Respiratory Tract Infection |
5.9% |
| Wheezing |
5.7% |
| Pneumonia |
5.5% |
| Respiratory Disorder |
4.1% |
| Viral Infection |
3.9% |
| Cough |
3.6% |
| Dyspnoea |
3.4% |
| Respiratory Syncytial Virus Bronchiolitis |
3.0% |
| Nasopharyngitis |
3.0% |
| Respiratory Syncytial Virus Test Positive |
2.5% |
| Apnoea |
2.1% |
| Respiratory Failure |
2.0% |
| Oxygen Saturation Decreased |
2.0% |
| Weight Decreased |
1.9% |
| Rhinorrhoea |
1.8% |
|
| Secondary |
| Antiviral Prophylaxis |
28.3% |
| Premature Baby |
24.5% |
| Bronchopulmonary Dysplasia |
19.9% |
| Heart Disease Congenital |
6.6% |
| Prophylaxis |
2.3% |
| Cardiac Disorder |
2.2% |
| Vitamin Supplementation |
2.1% |
| Respiratory Syncytial Virus Infection |
1.9% |
| Product Used For Unknown Indication |
1.8% |
| Pulmonary Hypertension |
1.4% |
| Cardiomyopathy |
1.2% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Infection Prophylaxis |
1.0% |
| Pneumonia |
0.9% |
| Antibiotic Prophylaxis |
0.9% |
| Epilepsy |
0.9% |
| Respiratory Disorder |
0.8% |
| Truncus Arteriosus Persistent |
0.8% |
| Atrial Septal Defect |
0.7% |
| Cardiac Failure |
0.7% |
|
| Respiratory Syncytial Virus Infection |
11.6% |
| Pyrexia |
8.8% |
| Vomiting |
8.5% |
| Wheezing |
8.0% |
| Dyspnoea |
6.9% |
| Respiratory Tract Infection |
6.2% |
| Cough |
5.8% |
| Pneumonia |
5.1% |
| Viral Infection |
4.8% |
| Respiratory Syncytial Virus Test Positive |
4.4% |
| Nasopharyngitis |
4.3% |
| Bronchiolitis |
4.0% |
| Death |
3.2% |
| Respiratory Disorder |
3.0% |
| Cyanosis |
2.8% |
| Upper Respiratory Tract Infection |
2.8% |
| Weight Decreased |
2.6% |
| Rhinorrhoea |
2.5% |
| Respiratory Syncytial Virus Bronchiolitis |
2.3% |
| Diarrhoea |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
34.7% |
| Product Used For Unknown Indication |
9.9% |
| Glycogen Storage Disease Type Ii |
8.9% |
| Bronchial Hyperreactivity |
5.9% |
| Drug Exposure During Pregnancy |
5.9% |
| Bronchitis Chronic |
5.0% |
| Pulmonary Hypertension |
4.0% |
| Systemic Lupus Erythematosus |
4.0% |
| Antiviral Prophylaxis |
3.0% |
| Cardiomyopathy |
3.0% |
| Ear Infection |
3.0% |
| Pulmonary Arterial Hypertension |
3.0% |
| Premature Labour |
2.0% |
| Tracheomalacia |
2.0% |
| Anticoagulant Therapy |
1.0% |
| Antiphospholipid Syndrome |
1.0% |
| Cough |
1.0% |
| Diarrhoea |
1.0% |
| Headache |
1.0% |
| Idiopathic Thrombocytopenic Purpura |
1.0% |
|
| White Blood Cell Count Abnormal |
14.8% |
| Pneumonia |
11.1% |
| Eye Movement Disorder |
7.4% |
| Inguinal Hernia |
7.4% |
| Small For Dates Baby |
7.4% |
| Abdominal Distension |
3.7% |
| Blindness |
3.7% |
| Blood Bilirubin Increased |
3.7% |
| Death |
3.7% |
| Ecchymosis |
3.7% |
| Hepatomegaly |
3.7% |
| Lung Disorder |
3.7% |
| Multi-organ Failure |
3.7% |
| Optic Atrophy |
3.7% |
| Respiratory Disorder |
3.7% |
| Subdural Haemorrhage |
3.7% |
| Tachycardia |
3.7% |
| Tracheostomy Infection |
3.7% |
| Upper Respiratory Tract Infection |
3.7% |
|
